Business Context and Reporting Period
This Form 8-K Current Report was filed by Kimberly-Clark Corporation (NYSE: KMB) on November 13, 2024. The filing reports a corporate governance event: the election of a new independent director to the Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on board composition changes.
Material Changes
- Board Expansion: The Board of Directors increased its size from 12 to 13 members.
- New Appointment: Joseph Romanelli was elected as an independent director and appointed to the Audit Committee, effective immediately.
- Background: Mr. Romanelli currently serves as President of Human Health International for Merck & Co., Inc., overseeing operations in over 75 markets outside the U.S.
Guidance, Outlook, and Management Commentary
CEO Mike Hsu stated that Mr. Romanelli's global leadership experience and expertise in science will benefit the company as it advances its "Powering Care" strategy. The filing notes that Mr. Romanelli will participate in the standard outside director compensation programs outlined in the company's 2024 proxy statement. No financial guidance or risk factors specific to this event were disclosed.
Key Facts for Investor Verification
- Verify the effective date of Joseph Romanelli's board membership (November 13, 2024).
- Confirm the new total number of directors (13).
- Review the 2024 proxy statement for details on director compensation applicable to Mr. Romanelli.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.